Study 106 Elvitegravir-Cobicistat-TAF-FTC in Treatment Nave - - PowerPoint PPT Presentation

Elvitegravir-Cobicistat-TAF-FTC in Adolescents

Study 106

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Design

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

Study Design: Study 106

• Background: Open-label, single arm phase

2/3 trial evaluating safety and efficacy of once- daily elvitegravir-cobicistat-tenofovir alafenamide-emtricitabine in treatment-naïve adolescents with HIV

• Inclusion Criteria (n = 50)
• Treatment-naïve adolescents with HIV
• Adolescents aged 12-18 yrs, ≥ 35kg
• HIV RNA ≥1000 copies/mL
• CD4 count ≥100 cells/mm3
• GFR ≥90 mL/min
• No resistance to EVG, FTC, or TDF
• Treatment Arms
• EVG-COBI-TAF-FTC

EVG-COBI-TAF-FTC

(n = 242)

Week 48 Week 0

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Result

Week 48 Virologic Response

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

92 6 1 20 40 60 80 100 HIV <50 copies/mL Virologic Failure No Virologic Data

Participants (%) EVG-COBI-TAF-FTC

46/50 3/50

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Result

Week 48: Changes in Quantitative Proteinuria

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

• 27.0
• 21.6
• 29.4
• 50
• 40
• 30
• 20
• 10

Proteinuria (UPCR) RBP/Cr β2M/Cr Median % Change from Baseline

Tubular Proteinuria RBP:Cr = retinol binding protein:creatinine ratio; β2M:Cr = beta-2 microalbumin:creatinine ratio

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Result

Week 48: Changes in Spine and Total Body Bone Mineral Density

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

3.3 0.9

1 2 3 4 5 Spine Total Body Less Head

Median % Change in BMD

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Common Adverse Events

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

Treatment Emergent Adverse Events in > 5% of Subjects Adverse Event EVG-COBI-TAF-FTC

(n = 50)

Nausea 20% Abdominal Pain 12% Vomiting 10% Upper Abdominal Pain 6% Diarrhea 6% Somnolence 6%

Elvitegravir-Cobicistat-TAF-FTC in Treatment Naïve Adolescents

Study 106: Conclusions

Source: Gaur AH, et al. Lancet HIV. 2016;3:e561-8.

Interpretation: “The elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and achieved component plasma pharmacokinetic exposures similar to those in adults. Although non-comparative with a small sample size, these data support the use of this regimen in HIV-infected adolescents and its timely assessment in younger children.”

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.